Pentobarbital will minimize the level or outcome of fentanyl transmucosal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with CYP3A4 inducers may lead to your decrease in fentanyl plasma concentrations, insufficient efficacy or, quite possibly, development of a withdrawal syndrome within a client who may have https://heinzt000pfs6.blogoscience.com/profile